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In this article, we review the literature regarding the role of c-Jun N-terminal kinases
(JNKs) in cerebral and myocardial ischemia/reperfusion injury. Numerous studies
demonstrate that JNK-mediated signaling pathways play an essential role in cerebral
and myocardial ischemia/reperfusion injury. JNK-associated mechanisms are involved in
preconditioning and post-conditioning of the heart and the brain. The literature and our
own studies suggest that JNK inhibitors may exert cardioprotective and neuroprotective
properties. The effects of modulating the JNK-depending pathways in the brain and
the heart are reviewed. Cardioprotective and neuroprotective mechanisms of JNK
inhibitors are discussed in detail including synthetic small molecule inhibitors (AS601245,
SP600125, IQ-1S, and SR-3306), ion channel inhibitor GsMTx4, JNK-interacting
proteins, inhibitors of mixed-lineage kinase (MLK) andMLK-interacting proteins, inhibitors
of glutamate receptors, nitric oxide (NO) donors, and anesthetics. The role of JNKs in
ischemia/reperfusion injury of the heart in diabetes mellitus is discussed in the context
of comorbidities. According to reviewed literature, JNKs represent promising therapeutic
targets for protection of the brain and the heart against ischemic stroke and myocardial
infarction, respectively. However, different members of the JNK family exert diverse
physiological properties which may not allow for systemic administration of non-specific
JNK inhibitors for therapeutic purposes. Currently available candidate JNK inhibitors with
high therapeutic potential are identified. The further search for selective JNK3 inhibitors
remains an important task.
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INTRODUCTION
Studying the mechanisms of ischemia/reperfusion injury has a significant clinical relevance.
Cerebral ischemia/reperfusion injury induces an increase in transendothelial permeability and
blood-brain barrier damage in patients with stroke (Diaz-Cañestro et al., 2018; Liu et al.,
2018). Cardiac ischemia/reperfusion is associated with necrosis, cardiomyocyte apoptosis,
contractile dysfunction, and life-threatening ventricular arrhythmias (Girn et al., 2007; Monassier,
2008; Sharma et al., 2012). Ischemia/reperfusion injury may also essentially impact outcomes
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of vascularized tissue allotransplantation. Ischemia/reperfusion
injury results in abnormal tissue architecture, hypertrophy
of the cell nuclei, and powerful neovascularization in the
presence of mitochondrial degeneration. Muscle cell necrosis is
associated with a diffuse inflammatory infiltrate and vasculopathy
continuing for hours after exposure; nerves undergo Wallerian
degeneration (Messner et al., 2016). Recent studies have shown
that the c-Jun N-terminal kinase (JNK) pathway is involved in
ischemia/reperfusion injury (Ip and Davis, 1998; Nijboer et al.,
2010; Javadov et al., 2014) as well as in neuronal apoptosis, tumor
growth, and insulin resistance (Ji et al., 2015).
JNKs belong to a family of mitogen-activated protein kinases
(MAPKs), which are activated in response to various stress
stimuli such as ultraviolet radiation, oxidative stress, heat and
osmotic shock, and ischemia/reperfusion injury of the brain
and the heart (Knight and Buxton, 1996; Ip and Davis, 1998;
Armstrong, 2004; Bogoyevitch and Kobe, 2006; Duplain, 2006;
Bode and Dong, 2007). Multifunction and cooperation of MAPK
signaling pathways is essential in other organs and tissues, in
particular in eye wound healing and ischemic neuropathy (Luo
et al., 2016; Yao et al., 2017). The family of JNK includes
10 isoforms encoded by three genes: JNK1 (four isoforms),
JNK2 (four isoforms), and JNK3 (two isoforms) (Gupta et al.,
1996; Waetzig and Herdegen, 2005). JNK1 and JNK2 are found
in all cells and tissues of the body, while JNK3 is expressed
mainly in the heart, brain, and testicles (Bode and Dong,
2007). JNK involved in pathogenesis of many diseases such
as stroke, atherosclerosis, Alzheimer’s and Parkinson’s diseases
(Waetzig and Herdegen, 2005; Johnson and Nakamura, 2007).
Previous studies have shown that JNKs play an important
role in the regulation of inflammation, the signaling pathways
of apoptosis and necrosis and regulate several transcriptional
and non-transcriptional processes involved in the injury of
neurons and cardiomyocytes during ischemia and reperfusion
(Ip and Davis, 1998; Nijboer et al., 2010; Javadov et al.,
2014). JNKs also participate in the embryonic myocardial
development, metabolic regulation, and other physiological
processes including neuronal and immunological functions
involving gene expression, cytoskeleton dynamics, and cell
survival (Javadov et al., 2014).
Upstream, JNKs are activated by the MAP 2 kinases MAPK
kinase (MKK) 3, MKK4, andMKK7, which, in turn, are activated
by MAP 3 kinases (MKKKs), mixed lineage kinase (MLK)-
2, MLK-3, transforming growth factor-β-activated kinase-1
(TAK-1), tumor progression locus-2 (Tpl2) kinase, and apoptosis
signal-regulating kinase-1 (ASK1) (Guo et al., 2018). Upstream
kinases of MAPK cascade (MKK4 and MKK7) phosphorylate
and activate JNKs. The MAPK phosphatase (MKP) family
represents essential regulators of JNKs. Being members of the
cysteine-dependent dual-specificity protein phosphatase (DUSP)
family, they specifically regulate the phosphorylation and activity
of mammalian MAPKs (Guo et al., 2018).
Approximately a hundred of well-verified JNK substrates
are now recognized. Among others, they comprise nuclear
transcription factors (ATF2, c-Jun, Elk1, Myc), cytoplasmic
proteins regulating cytoskeleton dynamics (DCX, Tau, WDR62),
vesicular transporters or INK-interacting proteins JIP1/JIP3,
transmembrane receptors (for example, bone morphogenetic
protein receptor type 2, BMPR2), and mitochondrial proteins
(Mcl1, Bim) (Zeke et al., 2016). Transcription factors such
as c-Jun, activating transcription factor 2 (ATF2), Sp1, and
nuclear factors of activated T-cells (NFATc2 and NFATc3) are
substrates for phosphorylation-activated JNKs (Ip and Davis,
1998; Vlahopoulos and Zoumpourlis, 2004; Nijboer et al.,
2010). There are also numerous non-nuclear substrates of JNKs,
participating in the degradation of proteins, signal transduction,
and regulation of apoptotic cell death (Bogoyevitch and Kobe,
2006; Shao et al., 2006). Dephosphorylation by dual specificity
protein phosphatase (DUSP1/MKP-1) causes deactivation of
the kinase (Chaudhury et al., 2010). Folding proteins, such
as JNK-interacting proteins JIP-1 and Sab, and interaction
with organelles are essential for the regulation of JNK activity
(Wiltshire et al., 2004).
The heart and the brain are the two vital organs where
ischemia/reperfusion injury plays the most crucial role
causing the highest mortality and morbidity burden on the
society. This review focuses on the involvement of JNK
signaling in the pathophysiology of cerebral and myocardial
ischemia/reperfusion injury and the emerging approaches to
protect the heart and the brain.
JNK IN THE PATHOPHYSIOLOGY OF
ISCHEMIA/REPERFUSION INJURY
The well-defined regulation of JNK signaling pathways in
cerebral and myocardial ischemia/reperfusion injury are
summarized in Figures 1, 2.
JNK in Cerebral Ischemia/Reperfusion
Injury
Here we update information on the significance of JNK-mediated
signaling in the brain as previously discussed (Shvedova et al.,
2017). JNKs are involved in many neuropathological events
and also play role in physiological neuronal regulation (Kuan
et al., 2003). JNK signaling pathway plays a critical role in
mediating apoptosis following cerebral ischemia and reperfusion
(Pei et al., 2008). Numerous works show that the increased
JNK phosphorylation and activation of JNK-dependent pathway
occur after global and focal cerebral ischemia in rats and mice
(Hayashi et al., 2000; Irving and Bamford, 2002; Borsello et al.,
2003; Ferrer et al., 2003; Tian et al., 2005; Atochin et al.,
2016). Activation of JNK aggravates brain injury in stroke,
provoking inflammation and leading to ischemic cell death
(Davis, 2000). An important role of JNK in the mechanisms of
neuronal death and survival is confirmed by the experiments
with Jnk1−/− knockout mice where permanent middle cerebral
artery occlusion significantly expands the area of the infarction
with an increased expression of JNK3 in the penumbra (Brecht
et al., 2005). Considering that the cells in the infarct area undergo
necrosis, this observation does not contradict the fact that JNK
promotes cell apoptosis.
Ferrer and co-authors studied the distribution of
phosphorylated JNK (p-JNK) and its substrate c-Jun in the
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FIGURE 1 | Schematic presentation of JNK signaling pathway in cerebral ischemia/reperfusion injury. Reactive oxygen species (ROS) and nitric oxide (NO) eruption
after ischemia/reperfusion cause activation of MAP kinase kinases MLK3 and ASK1 that can phosphorylate MAP kinase kinases MKK4/7. Exogenous NO, generated
by exogenous NO donors, S-nitrosoglutathione (GSNO) and endogenous NO, generated by NO synthases, modulates ASK1 and MLK3 activity via its S-nitrosylation.
JNK dephosphorylation by DUSP1 causes deactivation of this MAPK. Following activation, JNK translocates to the nucleus and modulates the function of AP-1
transcription factor, which induces a change in gene transcription, resulting in biological responses such as inflammation and/or apoptosis. MLK inhibitors K252a and
CEP-1347, and JNK inhibitors SP600125, IQ-1S, and AS601245, block activities of MLK and phosphorylated JNK, respectively. Other stimulus and effects in the
figure are listed in the text. GSNO, S-nitrosoglutathione; NO, nitric oxide; NOS, NO synthase; ASK1, apoptosis signal-regulated kinase 1; MLK, mixed-lineage kinase;
SNO, S-nitrosylated sites of the ASK1 and MLK; MKK4/7, MAP kinase kinases 4/7; JNK, c-Jun-terminal kinase; p-JNK, phosphorylated JNK; JIP-1, JNK-interacting
protein; Akt, protein kinase B; Bad, Bcl-2-associated death promoter; DUSP1, dual specificity protein phosphatase; FOXO3a, transcription factor of Forkhead family.
early stages after reperfusion in the rat model of middle
cerebral artery occlusion (MCAO). The study showed that
nuclear phosphorylation of JNK and c-Jun is increased 4 h after
reperfusion in the central zone of the infarction; the increased
level of their cytoplasmic phosphorylation is seen in the area
between the intact and the infarction area (penumbra) (Ferrer
et al., 2003).
One of the mechanisms by which activation of JNK
contributes to neuronal apoptosis in ischemia and reperfusion
consists in phosphorylation of Bcl-2-associated death promoter
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FIGURE 2 | Schematic presentation of JNK signaling pathway in myocardial ischemia/reperfusion injury. ROS generation after ischemia/reperfusion leads to oxidation
of SH groups in thioredoxin and its dissociation from the complex with ASK1. Antioxidant enzymes (SOD and catalase) and small molecules with free radical
scavenging capacity (for example, salvianolic acid A) could attenuate the oxidative stress. JNK inhibitors SP600125, AS601245, and SR-3306 block activity of
phosphorylated JNK. Small molecule inhibitor SU3327 blocks the process of spontaneous folding of polypeptide chain in the JNK-binding domain of JIP that also
attenuates the JNK activation. Tat-SabKIM1, a retro-inverso peptide blocks interaction of JNK with mitochondria (not shown). Other stimulus and effects in the figure
are listed in the text. SOD, superoxide dismutase; Trx, thioredoxin; ASK1, apoptosis signal-regulated kinase 1; JNK, c-Jun-terminal kinase; p-JNK, phosphorylated
JNK; JIP-1, JNK-interacting protein; DUSP1, dual specificity protein phosphatase; MpostC, morphine postconditioning; TRAF3IP2, TRAF3 interacting protein 2.
(Bad) associated with anti-apoptotic protein Bcl-2, induction of
Bim and Fas proteins, caspase activation, as well as the release of
cytochrome c from the mitochondria (Kuan et al., 2003; Qi et al.,
2009). The study of JNK signaling pathway in Cornu Ammonis
area 1 (CA1) hippocampal neuronal apoptosis in gerbils showed
activation of caspases −3, −8, and −9 in the first few days after
transient cerebral ischemia as well as later release of cytochrome
c from the mitochondria at days 5–7 after the ischemia (Carboni
et al., 2005).
Proteins of Bcl-2 family play an important role in the
regulation of apoptosis in global and focal cerebral ischemia
(Zinkel et al., 2006; Wang et al., 2007; Rami et al., 2008).
After transient global ischemia Bad protein is phosphorylated
in the area of CA1 of the hippocampus. Protein kinase B
(Akt)-dependent phosphorylation of Bad at serine 136 enhances
the interaction of Bad with phosphopeptide-binding proteins
14-3-3 which prevent the dimerization of Bad with Bcl-
XL, inhibits the release of cytochrome c into the cytosol,
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and suppresses the activation of caspase-3 that ultimately
increases neuronal survival (Wang et al., 2007). Besides, activated
Akt1 attenuates the phosphorylation of Bad at serine 128
by downregulating activation of JNK1/2, thus limiting JNK-
dependent apoptosis. In contrast, phosphorylation of Bad at
serine 128 after brain ischemia/reperfusion injury occurs due to
the kinase activity of JNK1 and JNK2 (Wang et al., 2007). The
phosphorylation suppresses Bad interaction with 14-3-3 proteins,
which contributes to the apoptotic effect of Bad. It has been
reported that Akt can phosphorylate ASK1 on Ser83, which
results in the inhibition of apoptosis induced by ASK1 (Kim
et al., 2001). Akt can also phosphorylate MLK3 on Ser674 and
this causes MLK3 inactivation and the promotion of cell survival
(Barthwal et al., 2003).
Dephosphorylation of JNK by DUSP1 leads to JNK
deactivation (Keyse, 2008). It is expected that the DUSP1
can limit the increase in the JNK activity and reduce the death
of neurons in hypoxia and reperfusion (Koga et al., 2012).
JNK-interacting proteins JIP-1 and Sab play an important role
in the regulation of JNK activity (Barr et al., 2004; Beeler et al.,
2009). It should be noted that increased expression of JIP-1 is
detected in the brain (Beeler et al., 2009).
JNK in the Myocardial
Ischemia/Reperfusion Injury
In this section of the review, we provide new details on
the JNK-mediated signaling in the myocardium which we
briefly presented before (Shvedova et al., 2016). JNK-dependent
pathway is an important step in the pathological mechanisms of
myocardial hypertrophy and ischemia/reperfusion injury of the
heart (Javadov et al., 2014). JNK is activated in cardiac ischemia
and reperfusion and may be involved in the protective and
adverse processes in the myocardium (Fryer et al., 2001; Kaiser
et al., 2005; Rose et al., 2010;Wei et al., 2011; Javadov et al., 2014).
This activation of JNK is transient, but it may vary depending
on the severity and timing of oxidative stress during ischemia
and/or reperfusion (Knight and Buxton, 1996; Laderoute and
Webster, 1997; He et al., 1999; Fryer et al., 2001; Armstrong,
2004). Both protective and harmful effects of JNK are shown
in genetic models where Jnk1−/− and Jnk2 −/− knockout mice
or MAPK kinase 7 (MKK7) overexpression mice demonstrate
protective effects on cardiomyocytes in ischemia/reperfusion-
induced apoptosis in vivo (Kaiser et al., 2005). Despite the fact
that activation of JNK is insignificant duringmyocardial ischemia
due to coronary artery bypass surgery in humans, there is an
increase of JNK activity in cardiac tissue during reperfusion
(Talmor et al., 2000). Some effects of myocardial ischemia and
reperfusion can be reproduced in vitro by placing cardiomyocytes
in “ischemic” buffer and an oxygen-free atmosphere (usually
95% nitrogen and 5% carbon dioxide). This model of ischemia
and subsequent reoxygenation induce an increase in the levels
of phosphorylation and activity of JNK in neonatal H9c2
cardiomyocytes (He et al., 1999; Sun et al., 2012).
Chambers and co-authors showed that JNK-dependent
signaling leads to the generation of reactive oxygen species
(ROS), mitochondrial dysfunction, and loss of cardiomyocytes
(Chambers et al., 2013). It has been shown that sepsis can
induce processes similar to ischemic preconditions. Bacterial
lipopolysaccharide exposure protects isolated cardiomyocytes
against hypoxia-induced cell death via JNK-associated signaling
pathways (Walshe et al., 2015). Activation of JNKs significantly
contributes to myocardial ischemia/reperfusion injury during
heart transplantation (Vassalli et al., 2012). Recent data
demonstrated that JNK is involved in suppressing the
proliferation of mesenchymal stem cells. Considering that
the mesenchymal stem cells play an important role in recovery of
the heart from post-ischemic injury (Wu et al., 2011), prevention
of ischemia-mediated suppression of their proliferative activity
using JNK inhibitors may have therapeutic value for healing the
ischemic lesions.
JNKs are involved in the regulation of apoptosis of
cardiomyocytes through the activation of caspase-dependent
(Aoki et al., 2002) and caspase-independent pathways in the
mitochondria (Song et al., 2008; Zhang G. M. et al., 2009). One of
the pathophysiological mechanisms by which activation of JNK
contributes to cardiomyocytes apoptosis in ischemia/reperfusion
injury, is the regulation of Bad phosphorylation (Qi et al., 2009).
Bcl-2 inhibits apoptosis in many cellular systems, including
lymphohematopoietic and neuronal cells. Bcl-2 regulates cell
death by affecting the permeability of the mitochondrial
membranes and suppressing caspase through preventing the
release of cytochrome c from the mitochondria and/or binding
the apoptosis inducing factor (AIF) (Song et al., 2008). In
the rat model of heart ischemia/reperfusion injury in vivo,
administration of SP600125, an anthrapyrazolone inhibitor of
JNK that competes with ATP to inhibit the phosphorylation of
c-Jun, attenuates mitochondria-to-nuclear translocation of AIF,
cardiomyocyte apoptosis, and the size of necrosis (Song et al.,
2008; Zhang J. et al., 2009). The key processes involved in the
activation of apoptosis via JNK-dependent pathway occur in
the mitochondria. In general, functioning of the mitochondrial
proteins can be modulated through either phosphorylation or
nitrosylation, or through the changes in the protein localization.
Activation of mitochondrial JNK, rather than localization of
this enzyme to the mitochondria, contributes to autophagy
and apoptosis exacerbating the subsequent myocardial injury
(Xu et al., 2015). JNK activation in the mitochondria during
ischemia/reperfusion requires entry of Ca2+, the movement
of electrons to the electron transport chain proteins on the
inner membranes of the mitochondria, and ROS generation
(Dougherty et al., 2002, 2004). Thus, in the isolated rat heart
perfused immediately prior to ischemia with Ca2+-free media,
the activation of JNK is abolished (Knight and Buxton, 1996).
However, JNK has high binding ability with the mitochondria
through protein Sab.Moreover, pharmacological blocking of JNK
binding with Sab reduces the size of infarction in rat hearts
(Chambers et al., 2013). It should be noted that the activation
of mitochondrial JNK could slow down the respiration and
ATP production and thereby negatively affect the bioenergetic
mitochondrial function (Dougherty et al., 2004).
ROS could be generated by NADPH-oxidase, electron-
transport protein chains of the mitochondria, or they could arise
from other sources (Dougherty et al., 2002, 2004; Oshikawa et al.,
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2012; Khalid et al., 2016). ROS generation leads to activation of
JNK and protein kinase C (Frazier et al., 2007). The introduction
of H2O2 to the perfusion solution activates JNK in the isolated
heart, although this activation is less pronounced than in the
ischemia/reperfusion model (Clerk et al., 1998). On the other
hand, the introduction of catalase and superoxide dismutase
(SOD) to the perfusion solution suppresses the activation of JNK
in cardiomyocytes (Knight and Buxton, 1996). In some models,
the activation of JNK can support generation of ROS. Adaptor
protein p66Shc-dependent ROS production via JNK-dependent
activation of NADPH-oxidase contributes to numerous pathways
including ischemia/reperfusion injury (Oshikawa et al., 2012;
Khalid et al., 2016). Application of JNK inhibitor SP600125
significantly reduces p66Shc phosphorylation at serine 36 in HL-
1 cardiomyocytes in ischemia/reperfusion model (Khalid et al.,
2016). Thus, JNK inhibitors could prevent activation of p66Shc
and subsequent oxidative stress.
JNK activation by ROS could be mediated via ASK1, which
is the upstream redox sensor of ROS generation in the MAPK
cascade with a high affinity binding to a reduced form of redox-
responsive protein thioredoxin, which prevents dimerization and
activation of ASK1 (Soga et al., 2012). Oxidative stress promotes
oxidation and dissociation of thioredoxin from the complex
and autophosphorylation of ASK1 (Kaminskyy and Zhivotovsky,
2014).
Cardio-specific protein MuRF1 regulates the size of
cardiomyocytes through its ubiquitin ligase activity, which
contributes to the subsequent degradation of sarcomere
proteins, as well as through interaction with transcription
factors that are involved in the molecular mechanisms of
cardiac hypertrophy (Li et al., 2011). Cardio-protective
properties of MuRF1 in myocardial ischemia/reperfusion are
due to suppression of JNK signal transduction pathways via
proteasome-dependent degradation of activated JNKs, as well as
decreasing cardiomyocytes apoptosis (Li et al., 2011). In contrast,
other ubiquitin ligase atrogin-1 causes a sustained activation
of JNKs through a mechanism that involves degradation of
MAPK phosphatase-1 (MKP-1) protein that leads to apoptosis
of cardiomyocytes after ischemia/reperfusion. SP600125 blocks
the effect of atrogin-1 on cell apoptosis and the expression of
apoptotic-related proteins and caspases (Xie et al., 2009).
JNK-associated mechanisms are involved in many regulatory
pathways of inflammation. Activated protein C (APC) is a
vitamin K-dependent plasma serine protease that downregulates
blood clotting and inflammatory pathways (Wang et al., 2011).
It is known that the APC exerts a cardioprotective effect by
decreasing JNK activity, reducing apoptosis of cardiomyocytes,
and suppressing expression of inflammatory mediators after
myocardial ischemia (Aoki et al., 2002). Likewise, nuclear
protein high-mobility group box 1 (HMGB1) is involved
in the myocardial inflammation and injury induced by
ischemia/reperfusion. This protein acts in concert with the
tumor necrosis factor (TNF) to promote ischemia/reperfusion-
induced myocardial apoptosis though JNK activation. It has been
shown that JNK inhibitor SP600125 prevents the cardiomyocyte
apoptosis induced by TNF/HMGB1 in vitro (Xu et al., 2011).
Additionally, macrophage migration inhibition factor (MIF)
is a proinflammatory cytokine, which plays an important
role in chronic inflammatory diseases. MIF reduces JNK
activation during reperfusion and protects the heart from
injury (Qi et al., 2009). Moreover, in the isolated heart of
Mif −/− knockout mice there is an enhanced JNK activation
(Qi et al., 2009). There is an assumption that, during
ischemia/reperfusion, endogenous MIF expressed in the heart
overwhelms JNK-dependent way through its specific receptor
CD74 and 5’AMP-activated protein kinase (AMPK). Advanced
glycation end-products (AGEs) bind to and trigger the receptor
for AGEs (RAGE), which is one of the major modulators
of inflammation. AGEs are also involved in the mechanisms
of acute ischemia/reperfusion injury of the heart (Shang
et al., 2010). Previously it has been shown that AGEs/RAGE
interaction transduces signals through activation of JNK and
other MAPKs, leading to activation of proapoptotic pathways
and cardiomyocyte death under hypoxia/reperfusion (Shang
et al., 2010). Finally, regulator of G-protein signaling 5 (RGS5)
can inhibit the activity of JNK1/2. RGS5 is highly expressed
in the human adult heart and is a guanosine triphosphatase-
activating protein that inhibits many pathways promoting
cardiomyocytes ischemia/reperfusion-induced apoptosis. This
mechanism protects the cardiomyocytes from apoptosis during
ischemia/reperfusion (Wang Z. et al., 2016).
JNK can also play a protective role. In particular, JNK
activates Akt via its phosphorylation of threonine 450 in a post-
ischemic injury (Shao et al., 2006). Decrease in Akt activity,
caused by JNK inhibition, reduces the survival of isolated
cardiomyocytes following hypoxia in vitro (Shao et al., 2006).
These data demonstrate that JNK participates in post-ischemia
Akt reactivation that might be the main mechanism of protective
effect of JNK in cardiomyocytes (Shao et al., 2006). Protective
role of JNK is also shown in cultural neonatal cardiomyocytes.
Treatment of cells with SP600125 leads to activation of caspase-3
and subsequent apoptosis (Engelbrecht et al., 2004).
Therefore, signaling mechanisms of JNK-dependent pathways
may adversely or positively affect the impact of other factors
involved in ischemia/reperfusion heart injury. The interaction of
JNKwith other kinases, such as p38, AMPK, protein kinase C and
Akt, plays an important role. Regulation of JNK activity involves
Ca2+ ions, various regulatory proteins and ROS. Signaling
molecules associated with JNK might be targets and effectors
of these interactions. Pro- and anti-apoptotic effects of JNK
in ischemia/reperfusion perhaps depend on the expression and
activation of these kinases and regulatory proteins as well as
on the intracellular redistribution of activated JNK between the
cytoplasm, mitochondria, and the nucleus of the cardiomyocytes.
JNK in Myocardial Ischemic Pre- and
Post-conditioning
The term “ischemic heart preconditioning” usually means short-
term (transient) ischemia, which leads to increased resistance of
the myocardium to injury associated with subsequent ischemia
and reperfusion. A few sessions of transient ischemia and
reperfusion exert cardioprotective effects (Maslov et al., 2013).
Despite similarity in the molecular mechanisms of cardiac
preconditioning and post-conditioning, several review papers
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stated JNK-dependent pathways differ between these processes
(Hausenloy and Yellon, 2006; Maslov et al., 2013). In most
experimental models, preconditioning induces activation of JNK
(Ping et al., 1999; Hausenloy and Yellon, 2007), whereas post-
conditioning is accompanied by the suppression of JNK activity
(Sun et al., 2006; Li et al., 2009; Zhang G. M. et al., 2009).
For example, cardiac preconditioning in rabbits activates the
phosphorylation of JNK at two amino acid residues; there are
important differences between p46 and p54 forms of JNK in
their subcellular localization in the cardiomyocytes (cytoplasmic
or nuclear fraction) and the mechanism of activation (ischemia
or reperfusion). Activation of p46-JNK occurs during ischemia,
whereas phosphorylation of amino residue 54 occurs after
reperfusion (Ping et al., 1999). However, Nakano and co-
authors were not able to detect JNK activation after ischemic
preconditioning in the model of the isolated heart (Nakano et al.,
2000). The cardioprotective effect of post-conditioning can be
caused by suppression of JNK activity in the myocardium. A
significant decrease in the level of phosphorylation is observed
in various models of ischemic post-conditioning (Liu et al.,
2006; Li et al., 2009; Zhang G. M. et al., 2009; Wei et al.,
2015), including post-conditioning with gradually increased
reperfusion (Zhang et al., 2014). Reduced phosphorylation of
JNK also occurs in isolated cardiomyocytes in the simulated
hypoxic post-conditioning model (Liu et al., 2008).
EFFECTS OF MODULATION OF JNK
ACTIVITY
Several synthetic inhibitors of enzymatic activity of JNK have
been described, including small molecules SP600125, AS601245,
IQ-1S, SR-3306; protein and non-protein molecules inhibiting
the interactions between JNK and their substrates or between
JNK and the folding proteins and/or cellular organelles have been
proposed as well (Irving and Bamford, 2002; Carboni et al., 2004,
2005; Gao et al., 2005; Guan et al., 2005; Kuan and Burke, 2005;
Pan et al., 2005; Krenitsky et al., 2012; Schepetkin et al., 2012;
Gehringer et al., 2015). However, a search for highly selective
JNK inhibitors, suitable for therapeutic purposes continues.
Some of these molecules show neuroprotective effects in the
animal models of stroke and myocardial infarction (Koch et al.,
2015; Atochin et al., 2016). Structures of several small molecule
inhibitors of JNK signaling pathway with therapeutic effects in
models of myocardial and cerebral ischemia/reperfusion injury
are shown in Table 1.
Inhibition of the JNK Activity in the Brain
Neuroprotective Effects of Small-Molecule Inhibitors
of JNK Activity
SP600125 is a cell penetrating inhibitor of JNK. This inhibitor
shows neuroprotection property in various models of
ischemia/reperfusion brain injury. The compound reduces
neuronal apoptosis and infarction volume and improves
stroke outcomes (Gao et al., 2005; Guan et al., 2005;
Murata et al., 2012). SP600125 inhibits neuronal apoptosis
induced by global ischemia followed by reperfusion in CA1
region of the hippocampus (Guan et al., 2006). SP600125
reduces phosphorylation of c-Jun and the expression of
Fas ligand (FasL), induced by ischemia/reperfusion in the
region CA1 of the hippocampus. It should be noted that
caspase-3 activation caused by ischemia/reperfusion is also
significantly inhibited by preliminary administration of
SP600125. Similar neuroprotective effect is observed after
administration of SP600125 before or after ischemia in rats.
Thus, SP600125 can inhibit the activation of JNK and provide
neuroprotection in ischemia/reperfusion in the area CA1 of the
hippocampus by suppressing neuronal apoptosis (Guan et al.,
2006).
Gao et al. studied JNK-dependent mechanism of apoptotic
neuronal death after focal ischemia/reperfusion injury in mice
(Gao et al., 2005). The researchers found an increase in the
activity of JNK in the brain 0.5–24 h after ischemia. Activation
of JNK induces serine phosphorylation of protein 14-3-3, which
leads to its dissociation from the Bax complex and translocation
of Bax to the mitochondria (Gao et al., 2005). The study also
showed that systemic administration of SP600125 reduces the
infarct volume and the ischemia-induced expression of Fas,
Bim and protein Hrk from the Bcl-2 family; it prevents Bax
and Bim translocation to the mitochondria, the release of
cytochrome c and proapoptotic protein Smac, and the activation
of the caspases−3 and−9 (Gao et al., 2005). It should be
noted, however, that SP600125 is relatively nonspecific. For
example, 13 of the 28 tested kinases were suppressed by
this compound at the same or even greater degree compared
with JNK (Bain et al., 2003). Therefore, it cannot be ruled
out that the observed protective effects of SP600125 during
ischemia/reperfusion are associated with the inhibition of other
kinases.
Although JNK inhibition at early stage of
ischemia/reperfusion reduces infarct volume and improves
stroke outcomes, delayed inhibition of JNK activity could
have the adverse effects on these parameters. For example,
in ischemia/reperfusion model, administration of SP600125
10min after the stroke reduces infarct volume, while the
administration of this inhibitor 7 days after the stroke increases
the volume of brain infarction and exacerbates neurological
disorders. Immune staining of near-infarction zone in samples
with delayed administration of SP600125 suggests the reduced
expression of neurovascular remodeling markers, including
matrix metalloproteinase-9 (MMP-9) in the astrocytes, as
well as the reduction of microvascular density network. Thus,
JNK, involved in neuronal death at the early stages, may also
be involved in the endogenous processes of neurovascular
remodeling and restoration after cerebral ischemia (Murata
et al., 2012).
Another JNK inhibitor, AS601245, also contributes to the
survival of cells after cerebral ischemia. The administration of
this inhibitor (intraperitoneally, at doses of 40, 60, and 80 mg/kg)
significantly reduces the loss of CA1 hippocampal neurons
in the model of transient global cerebral ischemia in gerbils
(Carboni et al., 2004). The administration of AS601245 at a
high dose of 80 mg/kg reduces damage to neuronal processes
and attenuates astrogliosis, contributing to the preservation of
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TABLE 1 | Small molecule inhibitors of JNK signaling pathway with therapeutic effects in models of myocardial and cerebral ischemia/reperfusion injury.
Name Molecular structure Molecular
target/mechanism
References
SP600125 JNK inhibitor Engelbrecht et al., 2004; Gao
et al., 2005; Guan et al., 2005,
2006; Song et al., 2008; Shi
et al., 2009; Xie et al., 2009;
Zhang J. et al., 2009; Xu et al.,
2011, 2015; Murata et al., 2012;
Khalid et al., 2016; Shao et al.,
2017
AS601245 JNK inhibitor Carboni et al., 2004, 2005,
2008; Li et al., 2015
IQ-1S JNK inhibitor Atochin et al., 2016
SR-3306 JNK inhibitor Chambers et al., 2013
CEP-1347 MLK inhibitor Carlsson et al., 2009
SU3327 blocks the folding of
polypeptide chain in the
JNK-binding domain of JIP
Jang and Javadov, 2014
Chemical names: SP600125, anthra[1-9-cd]pyrazol-6(2H)-one; AS601245, 1,3-benzothiazol-2-yl (2-{[2-(3-pyridinyl)ethyl]amino}-4 pyrimidinyl) acetonitrile; IQ-1S, 11H-indeno[1,2-
b]quinoxalin-11-one oxime sodium salt; SR-3306; N-(4-(3-(6-methylpyridin-3-yl)-1H-1,2,4-triazol-1-yl)phenyl)-4-(3-morpholinophenyl)pyrimidin2-amine; CEP-1347, (9S,10R,12R)-5-
16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3′ ,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl
ester; SU3327, 5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazol-2-amine.
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long-term memory in mice (Carboni et al., 2008). Significant
neuroprotective effect of AS601245 administration is observed
after intraperitoneal (6, 18, and 60 mg/kg) or intravenous
(1 mg/kg) administration in rats after focal cerebral ischemia
(Carboni et al., 2004). AS601245 protects hippocampal neurons
in the CA1 area from cell death, counteracting the activation
of both mitochondrial and non-mitochondrial pathways of
apoptosis (Carboni et al., 2005).
In the model of cerebral hypoxia/ischemia in 7-day old rats,
phosphorylation of JNK is accompanied by dephosphorylation
of the transcription factor of Forkhead family (FOXO3a) that
leads to the translocation of FOXO3a to the nucleus, which,
in turn, increases the level of expression of proapoptotic
protein Bim and caspase-3 (Li et al., 2015). Inhibition of JNK
by intracerebroventricular injection of AS601245 30min prior
to cerebral hypoxia/ischemia leads to a significant increase
in FOXO3a phosphorylation that attenuates the FOXO3a
translocation to the nucleus after the injury. In addition, the
inhibition of JNK reduces the levels of Bim and caspase-3,
decreasing the neuronal apoptosis and the area of infarction in
the brain of rats (Li et al., 2015).
Recently, a new JNK inhibitor with a dual action, IQ-
1S, has been described. This inhibitor also releases nitric
oxide (NO) as a result of bioconversion by microsomal
oxidoreductases (Schepetkin et al., 2012; Atochin et al.,
2016). Therapeutic efficacy of this JNK inhibitor has been
studied in mice with experimental cerebral ischemia and
reperfusion. Intraperitoneal administration of IQ-1S reduces
neurological deficit and infarction volume in comparison
with control animals 48 h after reperfusion (Atochin et al.,
2016).
JNK-Interacting Proteins and Indirect Modulation of
JNK-Dependent Pathway in the Brain
Synthetically designed peptide TAT-JBD consists of a sequence
of approximately 20 amino acids that corresponds to the
JNK binding domain (JBD) of JNK interacting protein (JIP)
coupled to the protein transduction sequence of HIV-TAT.
TAT-JBD inhibits the ensemble of complex JNK with JIP-
1, and therefore inhibits JNK activity. It should be noted
that this sequence increases the ability of molecules to
penetrate into the cell. Intraperitoneal administration of the
TAT-JBD peptide immediately after hypoxia/ischemia prevents
activation of the transcription factor AP-1 in rats (Nijboer
et al., 2010). Administration of TAT-JBD during the first
3 h after hypoxia/ischemia reduces neuronal damage. The
analysis of apoptotic cell death markers demonstrates that TAT-
JBD significantly reduces hypoxia/ischemia-induced activity of
caspase-3. However, administration of TAT-JBD does not inhibit
other factors mediating apoptosis such as the activation of
caspase-8, dissociation of Bid, and the release of mitochondrial
cytochrome c (Nijboer et al., 2010). TAT-JBD suppresses
hypoxia/ischemia-induced expression of Smac, an inhibitor of
apoptosis proteins (IAP). Application of TAT-JBD also reduces
cleavage of α-fodrin indicating a decrease in the calpain-
mediated brain injury. Neuroprotection, induced by TAT-JBD
administration, is long-lasting, as the damage to the gray and
white matter of the brain is decreased by 50% at week 14 after
hypoxia/ischemia along with the significant improvements in
behavior and cognitive functioning of rats (Nijboer et al., 2010).
Signaling pathway of JNKs can also be suppressed by blocking
the access to their protein substrates. One of such blockers is
D-retro-inverse protein D-JNKI-1 also based on TAT peptide
sequence. This inhibitor of JNK has been studied in several
models in vivo (Borsello et al., 2003; Wiegler et al., 2008) and
its neuroprotective properties have been demonstrated in animal
models of cerebral ischemia and stroke (Deloche et al., 2014).
Some synthetic antioxidants, including propyl gallate and
edaravone, show neuroprotective effects in the models of
ischemia/reperfusion injury and their effects are associated with
a reduction in the activity of JNK (Wen et al., 2006; Zheng et al.,
2006).
The activation of the calcium-sensing receptor (CaSR), a G-
protein coupled receptor, promotes apoptosis in focal cerebral
ischemia/reperfusion in male adult Kunming mice subjected
to 2-h focal cerebral ischemia followed by 22-h reperfusion,
which may be related to the activation of JNK/p38 MAPK
pathways. Ischemia/reperfusion increases CaSR expression
and induces neuronal apoptosis in the brain. Gadolinium
trichloride (GdCl3), an agonist of CaSR, further deteriorates
neurological dysfunction, increases infarct volume, enhances
CaSR expression, and promotes neuronal apoptosis. A low p-
JNK expression is detected in the cortex and hippocampus of
sham group, while p-JNK expression is significantly up-regulated
after ischemia/reperfusion. GdCl3 could further enhance the p-
JNK expression induced by ischemia/reperfusion, but p-JNK
expression is drastically inhibited by NPS2390, an inhibitor of
CaSR (Zhen et al., 2016).
In mouse cerebral ischemia/reperfusion injury model (2 h of
transient MCAO, followed by 24 h of reperfusion) penehyclidine
hydrochloride (PHC), a new cholinergic antagonist, significantly
downregulates the phosphorylation of JNK, p38MAPK, and c-
Jun and protects against cerebral ischemia/reperfusion injury.
PHC-treated mouse group in comparison with control group
shows improved neurological deficits, and blood-brain barrier
integrity as well as reduced infarction volume, brain water
content, and apoptosis (Shu et al., 2016).
Butylphthalide, which belongs to a family of compounds
initially isolated from the seeds of Apium graveolens,
administered intragastrically three times a day at a dosage of
15 mg/kg beginning at 20min after brain ischemia/reperfusion
in Sprague-Dawley rats, protects neurons against cerebral
ischemia/reperfusion-induced damage remarkably improving
the survival of CA1 pyramidal neurons in brain injury and
inhibits the JNK/caspase-3 signaling pathway. The expression of
p-JNK, p-Bcl-2, p-c-Jun, FasL, and cleaved caspase-3 is decreased
in the rats treated with butylphthalide (Wen et al., 2016). Precise
mechanisms of butylphthalide effects on JNK during cerebral
ischemia/reperfusion remain unknown.
Neuropeptide, a calcitonin gene-related peptide (CGRP)
improves the neurobehavioral function and reduces the cerebral
infarction area in rats subjected to ischemia/reperfusion
(MCAO model). Western blotting results confirm that the
function of the CGRP is mediated mainly through the reduction
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of the JNK and p38 phosphorylation and the promotion
of extracellular regulated kinase (ERK) phosphorylation
(Yang et al., 2016).
Atorvastatin, a hypolipidemic agent protects hippocampal
CA1 pyramidal neurons against cerebral ischemia/reperfusion
in four-vessel occlusion model in rats. Atorvastatin could
increase the phosphorylation of Akt1 and NO synthase diminish
the phosphorylation of JNK3 and c-Jun, and further inhibit
the activation of caspase-3. All of these protective effects
of atorvastatin are reversed by LY294002 [an inhibitor of
phosphatidylinositide 3-kinase (PI3K)]. Pretreatment with JNK
inhibitor SP600125 diminishes the phosphorylation of JNK3
and c-Jun, and further inhibits the activation of caspase-3 after
cerebral ischemia/reperfusion (Shao et al., 2017).
Anfibatide is a GPIb antagonist derived from the protein
complex agglucetin. Anfibatide has protective effects against
cerebral ischemia/reperfusion injury in rats in MCAO model.
The underlying mechanism may be associated with the
suppression of apoptosis through inhibiting toll-like receptor 4
(TLR4)/JNK/caspase-3 pathway (Luo et al., 2017).
Neuregulin-1β is a protein, which belongs to a four-
member family of epidermal growth factor-like signaling
molecules. Neuregulin-1β shows a neuroprotective effect
through the JNK signaling pathway in rats in MCAO
model of ischemia/reperfusion. Neuregulin-1β treatment
decreases JNK activity and the protein levels of p-JNK,
p-MKK4, and p-c-Jun. It also attenuates the ischemia-
induced apoptosis and infarct volume and recovers the
neurological function (Ji et al., 2017). Underlying mechanisms
of neuregulin-1β-mediated decrease in JNK activity are not well
understood.
Inhibitors of Mixed-Lineage Kinase (MLK) and
MLK-Interacting Proteins in the Brain
Pharmacological modulation of JNK activity may be achieved
by influencing the upstream elements of the signaling
pathway. Brain ischemia causes prolonged activation of the
MLK3/MKK7/JNK3 cascade (Pan et al., 2005). Introduction
of a microbial-origin alkaloid K252a (Kase et al., 1986), a
potent inhibitor of MLK3 and tyrosine protein kinase activities,
20min prior ischemia inhibits MLK3/MKK7/JNK3 signaling,
Bcl-2 phosphorylation, the activation of c-Jun and caspase-3
without significant effects on these protein expressions. K252a
also significantly increases the number of the surviving CA1
pyramidal cells at 5 days of reperfusion. These data demonstrate
that the alkaloid K252a plays a neuroprotective role in ischemic
injury by inhibiting the signaling pathways of JNK involving
apoptotic effector of caspase-3 (Pan et al., 2005).
Carlsson et al. also found that introduction of CEP-1347,
a synthetic analog of K252a and a potent inhibitor of MLK
family kinases has a protective effect due to suppression
of apoptosis of hippocampal neurons in the model of
neonatal hypoxia/ischemia (Carlsson et al., 2009). CEP-1347 also
demonstrated neuroprotective properties in vitro by blocking
JNK activation and subsequent events associated with the
activation of the JNK pathway in themodel of β-amyloid-induced
apoptosis (Bozyczko-Coyne et al., 2001). It should be noted
that CEP-1347 does not inhibit the enzymatic activity of JNK
(Maroney et al., 1998).
Global cerebral ischemia with subsequent reperfusion in
rat model of four-vessel occlusion ischemia can enhance the
binding of heat shock protein hsp90 with MLK3 and thereby
cause the activation of JNK3. Geldanamycin, an alkaloid of
microbial origin, is an inhibitor of protein chaperon hsp90 (Bedin
et al., 2004); hsp90 together with the p50cdc37 is required to
activate MLK (Zhang et al., 2004). Geldanamycin reduces the
expression of MLK3 protein and JNK activation and exhibits
neuroprotection in vivo and in vitro (Wen et al., 2008). However,
geldanamycin itself is an unfortunate drug candidate because
its administration in physiological concentrations is associated
with hepatotoxicity and eryptosis. This requires continuing
development of geldanamycin analogs with better safety profiles.
Glutamate Receptors Inhibitors Affect JNK Activity in
the Brain
Kainate glutamate subtype receptor (GluR6) plays an important
role in the ischemic brain through Glur6-PSD95-MLK3
signaling module, activation of kinases MKK4/7, and subsequent
phosphorylation of JNK and apoptosis factors (Pei et al., 2006; Du
et al., 2009; Di et al., 2012). It has been shown that the maximum
assembly of GluR6-PSD95-MLK3 module occurs at 6 h of
reperfusion (Tian et al., 2005). Pei and co-authors used antisense
oligonucleotides to GluR6 to suppress the expression of these
receptors. These oligonucleotides were intracerebraventricularly
injected to rats (once a day for 3 days) the transient ischemia of
the brain caused by four-vessel occlusion. The results showed that
the oligonucleotides to GluR6 suppress the expression of these
receptors, assembly of GluR6-PSD95-MLK3 signaling module,
JNK activation, and c-Jun phosphorylation and, ultimately,
protect neurons from death induced by ischemia/reperfusion
(Pei et al., 2005). Interestingly, hypothermia (32◦C) induced
10min prior ischemia and maintained for 3 h after ischemia can
also inhibit the assembly of the GluR6-PSD95-MLK3 signaling
module and the activation of MLK3, MKK4/7, and JNK3. The
hypothermia reduces phosphorylation of c-Jun and expression
of FasL, reduces translocation of Bax, the release of cytochrome
c, and caspase-3 activation in CA1 area of the hippocampus (Hu
et al., 2008).
NO Donors and JNK Activity in the Brain
More and more evidence suggests that JNK pathway is entangled
with enzymatic production of NO by NO synthases, and
subsequent S-nitrosylation of proteins during ischemia and
reperfusion (Yu et al., 2008). In contrast, exogenous NO donors
reduce S-nitrosylation of MLK3 protein caused by reperfusion
and inhibit the activation of JNK-dependent pathway (Hu
et al., 2012). NO donor, sodium nitroprusside, reduces JNK3
phosphorylation and damage of hippocampal neurons after
global ischemia/reperfusion (Pei et al., 2008). Other kinases
may be involved in NO-dependent modulation of JNK activity.
For example, S-nitrosylation of ASK1 by endogenous NO
activates JNK-dependent cascade during cerebral ischemia and
reperfusion (Liu et al., 2013). At the same time, exogenous NO,
generated by NO donors, such as sodium nitroprusside and
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S-nitrosoglutathione, suppresses S-nitrosylation of ASK1 and
protects neurons during ischemia/reperfusion (Liu et al., 2013).
Thus, exogenous NO donor can exert therapeutic effects through
modulating the MLK and ASK1 activities.
Neuroprotective Effects of Anesthetics and JNK
Activity
It has been shown that propofol, an intravenous anesthetic
and a modulator of ion channels TRPA1 and TRPA5 (Bahnasi
et al., 2008; Sinha et al., 2015), inhibits neuronal apoptosis in
ischemic stroke, protects the brain against ischemia/reperfusion
injury, and enhances neural function. Ji et al. studied the effects
of propofol (intravenous injection 30min post reperfusion)
in ischemia/reperfusion model with MCAO (Ji et al., 2015).
They demonstrated that the levels of water and Evans blue
(used for the evaluation of blood-brain barrier permeability to
macromolecules) as well as the expression of MMP-9 and p-JNK
in the brain are significantly reduced in propofol group (Ji et al.,
2015).
Other studies showed that isoflurane, an anesthetic and a
modulator of ion channel TRPA1 (Cornett et al., 2008), has
neuroprotective effects against ischemia/reperfusion injury in
the MCAO model. Isoflurane in concentrations up to 1.5% can
regulate the expression of transforming growth factor-β1 (TGF-
β1) and suppress the expression of p-JNK that significantly
attenuates ischemia/reperfusion injury. This protective effect
ceases when the signaling pathway of TGF-β1 is blocked by
LY2157299, a specific inhibitor of tyrosine kinase receptor for
TGF-β (Wang S. et al., 2016).
Cardiac Effects of Inhibiting JNK Activity
Synthetic Inhibitors of JNK Activity in the Heart
Pharmacological inhibition of JNK by various synthetic
inhibitors, such as AS601245, SP600125, and SR-3306 (Table 1),
reduces the size of myocardial infarction and attenuates
cardiomyocyte apoptosis after ischemia/reperfusion injury (Yue
et al., 2000; Ferrandi et al., 2004; Duplain, 2006; Liu et al.,
2007; Milano et al., 2007 ; Liu et al., 2008; Song et al., 2008;
Shi et al., 2009, Zhang J. et al., 2009; Xu et al., 2011; Chambers
et al., 2013; Khan et al., 2017). Introduction of SP600125 into
the solution for perfusion of the isolated mouse heart prior to
ischemia/reperfusion increases the resistance to opening the
mitochondrial permeability transition pore and protects the
myocardium against contractile dysfunction and necrosis during
ischemia/reperfusion (Zaha et al., 2016). Pretreatment with
SP600125 for 30min improves survival of the cardiomyocytes
after ischemia/reperfusion in vitro (Xie et al., 2009). This
inhibitor also increases cardioprotective effect of insulin in
ischemia/reperfusion injury (Liu et al., 2007). Application of
selective inhibitor of JNK, SR-601245, 5min before the end of
ischemia protects the myocardium during ischemia/reperfusion
in the experimental animal models. This inhibitor reduces
infarct volume and attenuates ischemia/reperfusion-induced
increases in the activity of creatine phosphokinase and creatine
kinase in blood (Chambers et al., 2013). However, a dual
inhibitor of MAPKs JNK and p38, compound V-150 when
administered prior to ischemia worsens cardiomyocyte apoptosis
and myocardial infarction in the animal model of prolonged
ischemia (Shao et al., 2006) emphasizing the relevance of
focusing on the effects of selective JNK inhibitors.
Effects of Indirect Modulation of JNK Activity in the
Heart
Indirect modulation of JNK activity in the heart may be a
promising approach for cardioprotection. For example, small
molecule inhibitor SU3327 (see Table 1) blocks the process of
spontaneous folding of polypeptide chain in the JNK-binding
domain of JIP (Jang and Javadov, 2014). The presence of this
inhibitor in the perfusion solution improves cardiac performance
of the isolated rat hearts and reduces myocardial injury
after ischemia/reperfusion (Jang and Javadov, 2014). Moreover,
inhibition of JNK1 expression in the cardiomyocytes in vitro
by using antisense oligonucleotides protects against ischemia-
induced apoptosis while silencing JNK2 does not produce similar
effect (Hreniuk et al., 2001).
Another example is a D enantiomer of a spider venom peptide
GsMTx4 (selective inhibitor of cationic mechanosensitive ion
channels), which shows cardioprotective effects in a mouse
model of ischemia/reperfusion. Administration of the GsMTx4-
D reduces infarct area and inhibits JNK/c-Jun, but also inhibits
the energy response Akt signaling system (Wang J. et al., 2016).
Interestingly, xanthine oxidase and xanthine dehydrogenase
have been shown to be implicated in production of myocardial
damage following reperfusion of an occluded coronary artery.
Febuxostat and allopurinol (xanthine oxidase inhibitors)
pretreatment exerts cardioprotective effects in rats subjected to
one-stage left anterior descending coronary artery ligation for
45min followed by a 60-min reperfusion. Suppression of the
active JNK and p38 proteins with the rise in ERK1/ERK2 is more
prominent after pretreatment with febuxostat in comparison
with allopurinol pretreatment (Khan et al., 2017).
Sodium hydrosulfide, NaHS, a donor of hydrogen
sulfide (H2S), is also a promising agent. In a simulated
ischemia/reperfusion model with primary cultured rat neonatal
cardiomyocytes, ischemia/reperfusion induces a rapid, time-
dependent JNK phosphorylation with significant elevation at 15
and 30min during reperfusion. Treatment with H2S significantly
inhibits the early phosphorylation of JNK, especially at 15min.
Both NaHS and JNK inhibitor SP600125 decrease the number
of apoptotic cells in a simulated ischemia/reperfusion model.
However, if NaHS application is delayed by 1 h after reperfusion,
the inhibition of apoptosis is negated (Shi et al., 2009).
Moreover, treatment with Tat-SabKIM1, a retro-inverso
peptide which blocks interaction of JNK with mitochondria,
decreases mitochondrial JNK activation without changing JNK
mitochondrial localization following reperfusion. Tat-SabKIM1
treatment reduces Bcl2-regulated autophagy, apoptosis, and
myocardial infarct size (Chambers et al., 2013; Xu et al., 2015).
Selective inhibition of mitochondrial JNK activation using Tat-
SabKIM1 peptide produces an infarct size-reducing effect similar
to inhibiting JNK with SP600125 (Xu et al., 2015).
Genetic modulation of signaling molecules upstream of
JNK has been used in the experiments to elucidate the JNK-
associated regulatory cascades. Cardiac DUSP1 is downregulated
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following acute cardiac ischemia/reperfusion injury. DUSP1
transgenic mice (DUSP1TG mice), compared to wild-type
mice, demonstrate a smaller infarcted area and the improved
myocardial function in vivo. The ischemia/reperfusion-induced
DUSP1 deficiency promotes the activation of JNK which
upregulates the expression of the mitochondrial fission factor
(Mff). The loss of DUSP1 amplifies the Bnip3 phosphorylated
activation via JNK, leading to the activation of mitophagy.
While the reintroduction of DUSP1 blunts Mff/Bnip3 activation
and alleviates the fatal mitochondrial fission/mitophagy by
inactivating the JNK pathway, providing a survival advantage to
myocardial tissue following ischemia/reperfusion stress (Jin et al.,
2017).
TRAF3IP2 (TRAF3 interacting protein 2; previously known
as CIKS or Act1) is an oxidative stress-responsive cytoplasmic
adapter molecule that is an upstream regulator of both IκB
kinase (IKK) and JNK. Ischemia/reperfusion up-regulates
TRAF3IP2 expression in the heart, and its gene deletion, in
a conditional cardiomyocyte-specific manner, significantly
attenuates ischemia/reperfusion-induced oxidative stress,
IKK/NF-κB and JNK/AP-1 activation, inflammatory cytokine,
chemokine, and adhesion molecule expression, immune cell
infiltration, myocardial injury, and contractile dysfunction
(Erikson et al., 2017).
Anesthesia Modulates JNK Activity in the Heart
Morphine post-conditioning (MpostC) markedly reduces
infarct size, creatine kinase MB isozyme release and improves
cardiac function recovery in isolated rat hearts subjected to
ischemia/reperfusion injury via inhibiting the phosphorylation
of JNK and p38 kinases, mitochondrial permeability transition
pore opening and cytochrome c release. These protective
effects are partially abolished in the presence of anisomycin (an
activator of JNK/p38 kinases) that totally reverses the inhibitory
effects of MpostC on the phosphorylation of JNK/p38 kinases,
permeability transition pore opening, and cytochrome c release.
However, when used individually, anisomycin does not influence
perfusion injury (Chen Z. et al., 2016).
Pharmacological Modulation of JNK
Activity in Diabetes Protects the Brain and
the Heart
Metabolic abnormalities represent one of the most essential
risk factors for myocardial infarction and stroke. Patients
with diabetes mellitus have worse clinical outcomes after
acute ischemic stroke (Rosso et al., 2015). The presence of
diabetes mellitus significantly modulates adaptive responses and
tolerance to ischemia and reperfusion. Glucagon-like peptide-
1 (GLP-1) is an incretin hormone that increases glucose-
dependent insulin secretion resulting in the reduction of the
glucose level. This molecule is involved in the pathogenesis
of type 2 diabetes mellitus due to defective glucose-stimulated
insulin secretion. Intracerebroventricular administration of GLP-
1 receptor agonist, exendin-4, after cerebral ischemia/reperfusion
injury reduces infarct volume in rats. JNK signaling is inhibited
by 36% within 24 h after exendin-4 injection. Islet-brain 1, a
scaffold regulator of JNK, is increased by 1.7-fold by exendin-
4 (Kim et al., 2017). A long-lacting GLP-1 analog, liraglutide,
exerts neuroprotective action in the experimental models.
Liraglutide inhibits cell apoptosis by attenuating excessive ROS
and improving the mitochondrial function in the neurons
suffering oxygen glucose deprivation in vitro and in vivo.
Liraglutide down-regulates the phosphorylation of JNK and p38
and augments the phosphorylation of Akt and ERK. Liraglutide
demonstrates therapeutic potential for patients suffering from
ischemic stroke, especially comorbid with type 2 diabetes mellitus
or stress hyperglycemia (Zhu et al., 2016).
Insulin selectively inhibits mitochondrial JNK activation,
contributing to the cardioprotective effects of insulin against
ischemia/reperfusion. A new antidiabetic drug, rosiglitazone (a
peroxisome proliferator-activated receptor (PPAR)-γ agonist)
is associated with suppressed JNK phosphorylation in cardiac
tissue of both normal and diabetes animals (Khandoudi
et al., 2002). In rat model of myocardial ischemia/reperfusion,
treatment with rosiglitazone significantly reduces myocardial
infarction in mice treated with rosiglitazone compared with
vehicle controls (Morrison et al., 2011). When rosiglitazone is
administrated simultaneously with onset of reperfusion, JNK-
dependent inflammatory response is inhibited, which greatly
improves recovery of the myocardium after ischemia/reperfusion
injury (Morrison et al., 2011). Insulin selectively inhibits the
activation of mitochondrial JNK, protecting the myocardium
against ischemia/reperfusion injury (Xu et al., 2015). Insulin
simultaneously activates both Akt and JNK, and the latter
further increases the phosphorylation of Akt which attenuates
ischemia/reperfusion injury and improves cardiac function (Liu
et al., 2007). Thus, the cross-talk betweenAkt and JNK is involved
in insulin-induced cardioprotection.
Metformin exerts direct protective effects against high-glucose
and hypoxia/reoxygenation injury in H9C2 rat cardiomyoblasts
via signaling mechanisms involving activation of AMPK and
suppression of high-glucose and hypoxia/reoxygenation-induced
JNK activation. Inhibitor of AMPK (compound C) and activator
of JNK (anisomycin) abolish the protective effects of metformin
(Hu et al., 2016).
Experimental evidence suggests that the JNK/PI3K/Akt
signaling pathway is involved in myocardial
ischemia/reperfusion injury in diabetic rats. Salvianolic
acid A, a water-soluble phenolic acid isolated from the root
of Dan Shen, shows an anti-apoptotic effect and improves
cardiac function following ischemia/reperfusion injury through
the JNK/PI3K/Akt pathway in this model. Pretreatment with
SP600125 and salvianolic acid A decreases the p-JNK levels,
increases the p-Akt levels, improves cardiac hemodynamics,
reduces infarct size and lactate dehydrogenase release, increases
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) type 2a
activity, decreases Bax and cleaved caspase-3 expression levels,
and increases Bcl-2 expression and Bcl-2/Bax ratio in diabetic
rats with ischemia/reperfusion injury (Chen Q. et al., 2016).
Salvianolic acid A exhibit stronger free radical scavenging
capacity and attenuated oxidative stress (Li et al., 2016; Zhu
et al., 2017) that could decrease activation of ASK1 and JNK
(Figure 2).
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Summary on Pharmacological Modulation
of JNK Activity
Promising small molecule agents which exert neuroprotective
and cardioprotective effects due to their direct inhibition of
JNK activity comprise SP600125, AS601245, IQ-1S, and SR-
3306 (Table 1). These compounds control the biological activity
of JNK at the level of phosphorylation and dephosphorylation
(Carboni et al., 2004, 2005, 2008; Gao et al., 2005; Guan
et al., 2005; Murata et al., 2012; Schepetkin et al., 2012;
Li et al., 2015; Atochin et al., 2016). Notably, IQ-1S, being
a NO-donating oxime and a JNK inhibitor, exerts dual
effects both contributing to neuroprotection (Atochin et al.,
2016).
The modes of indirect inhibition of JNK activity are
quite diverse and precise mechanisms of their protective
effects are often insufficiently understood. SU3327 is an
inhibitor that attenuates upstream JNK signaling rather than
the kinase activity (Jang and Javadov, 2014). Propyl gallate
reduces the immunoreactivity of JNK and p38 MAPKs and
their phosphorylated forms perhaps due to its antioxidant
properties (Wen et al., 2006). D-retro-inverse protein D-JNKI-
1 blocks JNK substrate (Borsello et al., 2003; Wen et al., 2006;
Wiegler et al., 2008). Penehyclidine hydrochloride downregulates
JNK/p38MAPK pathway (Shu et al., 2016) probably due to its
cholinergic antagonism. Exendin-4 inhibits phosphorylation of
the stress kinases including JNK and is not selective (Kim et al.,
2017). Adhesion receptor antagonist, anfibatide, inhibits toll-like
receptor 4 (TLR4)/JNK/caspase-3 pathway (Luo et al., 2017).
This agent is currently studied in phase II clinical trial for acute
coronary syndrome. MAPK phosphatase-1 mediates inactivation
of JNK when xanthine oxidase and xanthine dehydrogenase
activities are attenuated by the pretreatment with febuxostat
(Khan et al., 2017). Febuxostat exerts cardioprotective effects
in experimental animals, subjected ischemia/reperfusion, but,
according to FDA, this agent shows an increased risk of heart-
related death in patients.
Precise molecular mechanisms of modulation of JNK
signaling in ischemia/reperfusion remain unclear for many
agents showing neuroprotective potential. The list of such
agents with poorly understood mechanistic basis includes, but is
not limited, by the following: butylphthalide, atorvastatin,
CGRP, neuregulin-1β, and a microbial-origin alkaloid
K252a.
In summary, researchers have developed and experimentally
studied different approaches including administration of small
molecules directly blocking JNK activity as well as the proteins
and peptides of sophisticated design indirectly interfering with
diverse elements of the JNK-associated pathways. To progress
from bench to bedside, these approaches and agents require
thorough preclinical and, if relevant, clinical investigation to
assess their efficacy, safety, and tolerability. Cardioprotective
effects of known medications such as anesthetics and NO donors
are also sometimes associated with attenuation of JNK activity,
which opens the way to create new agents with safe profiles and
verified cardioprotective and neuroprotective efficacy based on
precursors with known molecular structures. Pharmacological
modulation of JNK signaling may be beneficial in reperfusion
events common in transplantation, coronary artery disease,
cardiac surgery, traumatic injury, and stroke.
JNKS AS POTENTIAL THERAPEUTIC
TARGETS
In the past two decades, JNKs have generated interest as potential
therapeutic targets for the prevention and treatment of ischemic
heart and brain injury (Irving and Bamford, 2002). JNKs are
involved in the pathogenesis of stroke, myocardial infarction,
diabetes, atherosclerosis, Alzheimer’s disease, Parkinson’s disease,
tumor growth, inflammatory diseases, congestive heart failure
and myocardial hypertrophy (Farrokhnia et al., 2005; Waetzig
and Herdegen, 2005; Bode and Dong, 2007; Johnson and
Nakamura, 2007; Javadov et al., 2014; Ma et al., 2016). Inhibition
of JNKs could influence the pathogenesis of these diseases.
However, the diversity of physiological properties of JNKs
and cross-talk of JNK-dependent pathway with other signaling
systems do not allow for systemic use of the non-specific
inhibitors affecting the activity of all three isoforms (JNK1, JNK2,
and JNK3). Although, several JNK inhibitors with acceptable
pharmacokinetics (Gehringer et al., 2015) are currently available,
a complete non-specific inhibition of these JNK isoforms would
be inappropriate in the treatment of these diseases. However,
selective downregulation of individual JNK isoforms (first of
all, JNK3 expressed in the brain) or targeting the specific
molecular domains of JNK-dependent cascades involved in
pathological signal transduction may be promising (Waetzig and
Herdegen, 2005; Messoussi et al., 2014). A search for highly
selective and nontoxic inhibitors of JNK and JNK pathway
continues in order to identify agents with high therapeutic
potential. Since JNK3 is expressed in the brain and the heart,
the development of selective inhibitors for this isoform may be
promising and therapeutic efficacy of new compounds should
be studied in appropriate ischemia/reperfusion models. A new
inhibitor of JNK IQ-1S (11H-indeno[1,2-b]quinoxalin-11-one
oxime sodium salt) represents such a high-interest candidate
compound. IQ-1S has high affinity to JNK3 and protects the
brain after experimental stroke in rats (Atochin et al., 2016).
Importantly, pharmacological modulation of JNKs must take
into account the presence of comorbidities where JNK could
also play an important role. Indeed, diabetic hyperglycemia
worsens the ischemic damage to the brain and is associated
with JNK phosphorylation in cortical neurons in the experiment
(Farrokhnia et al., 2005; Ma et al., 2016). Even in the
presence of moderate ischemia, JNK activation is observed on a
contralateral side in hyperglycemic rats (Farrokhnia et al., 2005).
Cardioprotective and neuroprotective effects of new selective
JNK inhibitors, including IQ-1S, should be further explored in
the models of ischemia and reperfusion in comorbid animals.
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